SkinBioTherapeutics (GB:SBTX) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SkinBioTherapeutics has finalized a commercial agreement with Croda Beauty Care, marking a significant step towards launching its SkinBiotix technology in the cosmetics market. The company anticipates becoming cash flow positive by FY2025, driven by expected sales from the Croda deal and recent acquisitions such as Dermatonics and Bio-Tech Solutions. The launch of SkinBiotix as an active ingredient is set for April 2025 at the In-Cosmetics Global exhibition in Amsterdam.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue